Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
60.72
+0.73 (+1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
18
19
Next >
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
July 06, 2023
BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles.
Via
MarketBeat
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
↗
July 05, 2023
BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
↗
July 05, 2023
Via
Benzinga
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
↗
July 03, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
↗
June 14, 2023
Via
Benzinga
Death Cross Looms Over Biomarin Pharmaceutical Investors
↗
May 02, 2023
Via
Benzinga
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
↗
April 27, 2023
Via
Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
↗
June 30, 2023
On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults
Via
Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
↗
June 30, 2023
New York Post
Via
Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
↗
June 30, 2023
The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency...
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
↗
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
↗
April 25, 2023
Via
Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
↗
March 21, 2023
Via
Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
↗
June 22, 2023
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.
Via
InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
↗
June 20, 2023
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of...
Via
SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
↗
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
May 26, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 25, 2023
Via
Benzinga
3 Biotech Stocks With Blockbuster Potential
↗
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
↗
May 17, 2023
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
↗
April 20, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
↗
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
↗
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
↗
March 28, 2023
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story.
Via
The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
↗
March 21, 2023
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
↗
March 21, 2023
Via
Benzinga
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
↗
March 08, 2023
Via
Benzinga
Why BioMarin Shares Are Plunging Today?
↗
March 06, 2023
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.
Via
Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
↗
March 06, 2023
The company is testing a drug for children with achondroplasia, a cause of dwarfism.
Via
Investor's Business Daily
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
